<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03232619</url>
  </required_header>
  <id_info>
    <org_study_id>SHBYCL001</org_study_id>
    <nct_id>NCT03232619</nct_id>
  </id_info>
  <brief_title>CD19-CART Treatment for ALL</brief_title>
  <official_title>Safety and Efficacy Evaluation of CD19-CART Treatment for Refractory or Recurrent ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Bioray Laboratory Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Bioray Laboratory Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and efficacy of a novel CD19-CART in the treatment of
      refractory or recurrent ALL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chimeric antigen receptor T cell (CART) is a kind of engineered immunotherapy by transferring
      an artificial antigen binding receptor and also intercellular co-stimulating molecules into T
      cells. This kind of engineered T cells gains the ability to recognize antigen specific tumor
      cells and initiate the killing process in a HLA-independent way. CD19 is the specific
      cellular marker of B lineage acute leukemia (B-ALL), thus CD19-CART will be efficient in
      treating B lineage ALL. The investigators have constructed two kinds of CD19-CART. One is
      equipped with a murine CD19 scFv (single-chain variable fragmentt), while the other with a
      humanized scFv. This study aims to evaluate the safety and efficacy of both murine and
      humanized CD19-CART in treating refractory or recurrent ALL.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Enrolled patients will receive CD19-CART cell immunotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiological assessment</measure>
    <time_frame>Month1 to Month12</time_frame>
    <description>Radiological assessment of the therapeutic effect by systemic or local computed Tomography(CT) or positron emission tomography scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of CART immunotherapy</measure>
    <time_frame>Day 1 to Week 4</time_frame>
    <description>After CAR-T cell infusion,we will observe the potential adverse events, especially Cytokine Release Syndrome (CRS) and neurotoxicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>CD19-CART with a murine scFv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients in this arm will receive CD19-CART with a murine scFv.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>humanized CD19-CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients in this arm will receive humanized CD19-CART.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19 CART</intervention_name>
    <description>Patients will get one course of CART treatment with the dose of 2*10~6/KgBW.</description>
    <arm_group_label>CD19-CART with a murine scFv</arm_group_label>
    <arm_group_label>humanized CD19-CART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. previously identified as CD19+ ALL.

          2. ALL patients not eligible for allogeneic SCT or relapse after allogeneic SCT.

          3. Expected survival &gt;12W.

          4. Creatinine &lt; 2.5 mg/dl.

          5. Alanine transaminase (ALT)/Aspartate Aminotransferase (AST) &lt; 3x normal

          6. Bilirubin &lt;2.0 mg/dl

          7. Voluntary informed consent is given.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Uncontrolled active infection.

          3. Active hepatitis B or hepatitis C infection.

          4. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not
             exclusionary.

          5. Previously treatment with any gene therapy products.

          6. Any uncontrolled active medical disorder that would preclude participation as
             outlined.

          7. HIV infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingsong Zeng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Li, pHD</last_name>
    <phone>+8618621670308</phone>
    <email>adamweili@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Bioray Inc.</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200240</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wei Li, PhD</last_name>
      <phone>+8618621670308</phone>
      <email>adamweili@126.com</email>
    </contact>
    <investigator>
      <last_name>Jinsong Zeng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

